New and improved antibiotics are urgently needed to combat the ever-increasing number of multidrugresistant bacteria. In this study, we characterized several members of a new oxazolidinone family, R-01. This antibiotic family is distinguished by having in vitro and in vivo activity against hospital-acquired, as well as community-acquired, pathogens. We compared the 50S ribosome binding affinity of this family to that of the only marketed oxazolidinone antibiotic, linezolid, using chloramphenicol and puromycin competition binding assays. The competition assays demonstrated that several members of the R-01 family displace, more effectively than linezolid, compounds known to bind to the ribosomal A site. We also monitored binding by assessing whether R-01 compounds protect U2585 (Escherichia coli numbering), a nucleotide that influences peptide bond formation and peptide release, from chemical modification by carbodiimide. The R-01 oxazolidinones were able to inhibit translation of ribosomes isolated from linezolid-resistant Staphylococcus aureus at submicromolar concentrations. This improved binding corresponds to greater antibacterial activity against linezolid-resistant enterococci. Consistent with their ribosomal A-site targeting and greater potency, the R-01 compounds promote nonsense suppression and frameshifting to a greater extent than linezolid. Importantly, the gain in potency does not impact prokaryotic specificity as, like linezolid, the members of the R-01 family show translation 50% inhibitory concentrations that are at least 100-fold higher for eukaryotic than for prokaryotic ribosomes. This new family of oxazolidinones distinguishes itself from linezolid by having greater intrinsic activity against linezolid-resistant isolates and may therefore offer clinicians an alternative to overcome linezolid resistance. A member of the R-01 family of compounds is currently undergoing clinical trials.
The marked increase in infections caused by multidrug-resistant bacteria underscores the urgent need for new agents to combat infections. This need has made the search for new antibacterials a critical, but very challenging, endeavor. Despite this acute need and extensive research, antibiotics from only two new chemical classes of compounds have been approved in the last 30 years: the lipopeptide daptomycin (25) and the oxazolidinone linezolid (4) . Oxazolidinones are a class of synthetic antibiotics that originated from a series of oxazolidinones reported to be useful for treating a variety of plant diseases (16) . Their antibacterial activities were discovered during the course of a screening program for antibacterials (44) . Early on, oxazolidinones were found to exert their actions through the inhibition of protein synthesis (14) .
Linezolid (Zyvox), which was approved by the FDA for human use in 2000, has in vitro and in vivo activity against multidrug-resistant gram-positive organisms, such as methicillin-resistant Staphylococcus aureus. The first reports of bacterial strains resistant to linezolid started to appear shortly after linezolid's introduction into the clinic (2, 49) . Although the number of strains resistant to linezolid is still low (1, 23) , there are several recent reports about linezolid resistance involving different clinical settings (10, 38, 41) . In almost all cases, resistance to linezolid in a variety of clinical isolates affects the large ribosomal subunit (50S) via a nucleotide mutation resulting in G2576U (Escherichia coli numbering) for one or more alleles of 23S rRNA (1, 24) .
The link between linezolid resistance and the bacterial 50S ribosomal subunit is supported by a wealth of biochemical studies, which show that the oxazolidinones bind to a site in the ribosome that overlaps the binding sites of lincosamides and chloramphenicol (28, 48) . The binding overlap of linezolid with lincosamide antibiotics is also supported by the X-ray structure of linezolid bound to the 50S ribosomal subunit of Haloarcula marismortui (20, 45) , Protein Data Bank ID code 3CPW. Furthermore, in ribosome function assays, linezolid shows cross-resistance to chloramphenicol (5) . Like chloramphenicol, linezolid suppresses nonsense mutations and promotes frameshifting (48) . In addition, oxazolidinone-resistant mutants isolated in the laboratory are linked to mutations around the peptidyl transferase region (24, 47, 52) .
Using a combination of structural information and computational analysis, we developed a new oxazolidinone family, R-01. This family is effective against drug-resistant bacteria found in community and hospital settings. Members of the R-01 family were designed to have higher affinity for the ribosome than linezolid, thereby overcoming resistant strains and conquering major causative agents in the community, such as streptococci, Moraxella, or Haemophilus. We used detailed knowledge at the atomic level of the juxtaposition of the ribofunctional loci of linezolid and sparsomycin (15, 20) . We identifed an optimal bridging element between these molecules that gives priority to interactions and shape complementarity with the ribosome. Based on the atomic structures of R-01-ribosome complexes, energy analysis, and biological data generated for the initial set of molecules, three key computational models were developed and validated (50) . The models were used to improve H. influenzae activity, to predict Caco-2 cell permeability (a surrogate for oral absorption) (11) , and to predict rat oral bioavailability. The use of this integrated structure-based drug design approach allowed us to identify a new family of oxazolidinones that balanced all features, including potency and desired properties, for this series. These new oxazolidinones form the basis of Rib-X's R-01 program and have led to one compound of the R-01 family entering phase 2 clinical trials.
In our study, several members of the R-01 family of novel oxazolidinones were compared to linezolid. This comparison was based on the R-01 ability to displace chloramphenicol or puromycin from the 50S ribosomes and on the ability of the oxazolidinones to inhibit the translation of 70S ribosomes isolated from linezolid-susceptible and -resistant (G2576U mutation) S. aureus. Our study showed that chemical modification of U2585 (E. coli numbering), a 23S rRNA nucleotide that influences peptide bond formation and peptide release, was hindered by the presence of R-01 compounds but not by the presence of linezolid. In addition, we also discovered that the R-01 family binds the 50S ribosomal subunit more strongly than linezolid. As a consequence, R-01 compounds, compared to linezolid, show enhanced antibacterial activity and a stronger ability to promote translational inaccuracy. Furthermore, in translation assays, R-01 compounds are able to overcome the ribosomal mutation found in most linezolid-resistant clinical isolates, suggesting that R-01 compounds may be ideal candidates to combat linezolid resistance in the clinic.
MATERIALS AND METHODS

Antibiotics.
Compounds Rx-01_002, Rx-01_007, Rx-01_133, Rx-01_149, Rx-01_413, Rx-01_423, Rx-01_445, and Rx-01_667 (9, 34) and linezolid (7) Preparation of S. aureus 70S ribosomes. Ribosomes were prepared according to the method of Rheinberger et al. (37) with small modifications to adapt the protocol for S. aureus. Briefly, an overnight culture of S. aureus was used to inoculate fresh tryptic soy broth medium. Bacteria were grown at 37°C to an optical density at 600 nm of 2 and cooled to 0°C to produce runoff (empty) ribosomes. Cells were harvested and frozen in liquid nitrogen. Frozen S. aureus cells were resuspended in TMKPL buffer [10 mM Tris, pH 8.2, with acetic acid, 14 mM Mg(OAc) 2 , 60 mM KCl, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, and 100 units/ml lysostaphin] at 4°C. The cell suspension was lysed by three consecutive passes through an EmulsiFlex-C5 microfluidizer (Avestin, Ottawa, Canada) cell, followed by the addition of DNase I to a final concentration of 1 unit/ml of the cell extract. The supernatant was centrifuged at 30,000 ϫ g for 20 min at 4°C. The upper three-fourths of the resulting supernatant was mixed with 1.1 M sucrose (0.24 ml per ml of supernatant) and was centrifuged again at 30,000 ϫ g for 2 h at 4°C. The cleared supernatant was loaded on a 1.1 M sucrose cushion and was centrifuged at 100,000 ϫ g for 16 h. The ribosome pellet was suspended in TMK buffer and dialyzed for 2 h at 4°C against the same buffer, frozen in liquid nitrogen, and then stored at Ϫ80°C. Ribosomes (70S) were prepared from S. aureus (Lin r Erm r ) in a fashion similar to S. aureus wild-type ribosomes except that the cells were grown in medium with erythromycin (50 g/ml) to ensure a high level of A2058 methylation.
Translation inhibition assays. To test inhibition by R-01 compounds of protein synthesis, we developed several prokaryotic in vitro translation-only assays. We developed these assays by modifying a previously described transcription/translation assay fueled with an E. coli S30 extract (Promega part number L1020) (35a). The translation-only assay uses purified S. aureus 70S ribosomes (20 nM final concentration) in TMK buffer (10 mM Tris-HCl, pH 7.4, 6 mM MgCl, 60 mM KCl, 1 mM dithiothreitol), various amounts of S100 extracts from different bacterial sources, Promega amino acid mix (0.1 mM final concentration), 3 l of Promega S30 premix, and 200 to 800 nM (final concentration) of an in vitro-transcribed mRNA encoding firefly luciferase. The final volume of each translation reaction mixture was 10 l. All compounds were tested in duplicate for translation inhibition, and all assays included both positive and negative 3 H]puromycin and increasing concentrations of unlabeled control antibiotics or R-01 compounds to assess the binding competition. Ribosomes were separated from unbound compounds by spin column chromatography using Bio-Gel P-30 from Bio-Rad equilibrated with TMK buffer. The degree of radioactive chloramphenicol or puromycin displacement was quantified via scintillation counting (53) . The apparent IC 50 was defined as the concentration of compound that displaced 50% of the bound chloramphenicol under fixed nonequilibrium conditions and was calculated using Prism V4 (GraphPad Software Inc.). Etamycin, griseoviridin, and tylosin were used to validate the method (data not shown).
RNA footprinting. To determine whether R-01 compounds protect 23S rRNA bases from chemical modification, 70S ribosomes (50 to 200 nM) were incubated for 10 min at 37°C, followed by 10 min at 20°C in 50 l of the corresponding modification buffers (46) containing 0.1 to 1 mM antibiotics. 1-Cyclohexyl-3-(2-morpholinoethyl) carbodiimide metho-p-toluene sulfonate (CMCT) and dimethyl sulfate modifications were carried out at 37°C or at room temperature, as described previously (31) . Primer extension was performed in the presence of [␣- 33 P]TTP according to the method of Stern et al. (46) with a set of primers specific for either E. coli or S. aureus 23S rRNA, depending on the source of ribosomes used in the experiment. Dried gels were exposed and bands were quantified with a "Storm" scanner (Molecular Dynamics).
Translational-accuracy assay. To perform translational-accuracy assays, E. coli strains containing plasmids to test translational accuracy (48) were incubated with sub-MIC concentrations of test compounds. In these strains, the level of ␤-galactosidase activity is dependent on the abilities of the test compounds to promote either a ϩ1/Ϫ1 frameshift event or a stop codon readthrough. Each experimental point was generated by averaging the results of three separate assays measured in duplicate (33) . E. coli MC245 containing one of four different lacZ plasmids was used to determine the level of translational inaccuracy caused by R-01 compounds. Two of the constructs allowed us to test for either ϩ1 frameshifting or Ϫ1 frameshifting, while the other two constructs allowed us to test for stop codon readthrough of either UAG or UGA stop codons. Because the levels of ␤-galactosidase produced from each of the reporter plasmid constructs varied in the absence of antibiotic, the values for the zero drug controls were set at one to allow direct comparison between constructs. Reporter cells were grown to an optical density at 600 nm of 0.3 in the presence (12 to 14 h) or in the absence (4 h) of subinhibitory drug concentrations (48) .
RESULTS
R-01 compounds overcome ribosome-based linezolid resistance. We compared the ability of the R-01 family of oxazolidinones to inhibit bacterial protein synthesis to that of linezolid in a translation-only assay using ribosomes isolated from two different sources: S. aureus ATCC 29213 (wild type) or S. aureus A7820 (Lin r Erm r ). S. aureus A7820 has a plasmid carrying ermC methylase, as well as a G2576U mutation in each allele of 23S rRNA. Most linezolid resistance in staphylococci and enterococci isolated in clinical settings is due to this G2576U mutation (22, 36, 38, 39, 49, 51) . Our results indicated that R-01 compounds inhibit translation fueled by S. aureus wild-type ribosomes up to Ն45-fold better than linezolid (Table 1) . When translation was mediated by Lin r Erm r S. aureus ribosomes, there was a 10-fold increase in the IC 50 for linezolid and only at most a Յ4-fold increase for R-01 compounds compared to wild-type values. Furthermore, the abilities of the R-01 compounds to bind tightly enough to ribosomes to overcome ribosome-based linezolid resistance do not come at the expense of selectivity. Translation assays showed that most R-01 compounds are at least 100-fold less active in inhibiting translation in rabbit reticulocytes than in S. aureus ribosomes. Thus, R-01 compounds not only bind more tightly to ribosomes than linezolid, they also display a selectivity ratio comparable to that of linezolid (Table 1) . Antimicrobial activities of R-01 compounds. We determined MICs on linezolid-susceptible and -resistant S. aureus and enterococcal clinical isolates bearing the G2576U mutation. Our study showed that all members of the R-01 family were equally or more effective than linezolid in inhibiting the growth of S. aureus and E. faecalis strains susceptible to linezolid (S. aureus QC [ Table 2 ]). When potency at the ribosomal target was assessed by in vitro translation assays, most members of the R-01 family of novel oxazolidinones, in contrast to linezolid, chloramphenicol, and florfenicol, overcame resistance linked to the G2576U mutation. Although the IC 50 s in translation for S. aureus Lin r Erm r ribosomes (Table 1) did not always mirror the ranking of R-01 compounds according to their antibacterial activities compared to linezolid-resistant strains (Table 2 ), in every case the R-01 compounds were more potent than linezolid against linezolid-resistant isolates, (26) . R-01 compounds protect nucleotide U2585 of 23S rRNA. To determine the binding target of R-01 compounds, we also made use of chemical modifications of 23S rRNA. Our study showed that nucleotide U2585 is protected from CMCT modification in the presence of chloramphenicol but not in the presence of linezolid, despite overlapping binding sites (37) (Fig. 2B) . Interestingly, nucleotide U2585 is protected from CMCT modification by the binding of R-01 compounds ( Fig.  2A and B) . The level of U2585 protection attained in the presence of R-01 compounds (40 to 60%) is comparable to that of chloramphenicol (50%) and lower than that of florfenicol (80%). A similar pattern of protection was observed for other compounds that bind to the 50S ribosomal A site (e.g., tiamulin and streptogramin A) (data not shown). These results are in good agreement with the crystallographic structures obtained for various R-01 compounds bound to the 50S ribosomal subunits of H. marismortui (21) and confirm that R-01 compounds interact with the ribosome in a manner notably different from that of conventional oxazolidinones.
Determining the structure of linezolid bound to H. marismortui 50S required crystals to be soaked in Ͼ4 mM linezolid, a concentration that is at least 40 times higher than the concentration used in the chemical protection experiments. The high concentration needed to obtain the structure of linezolid gives additional support to the inability of linezolid, in contrast to R-01 compounds, to protect U2585 at submillimolar concentrations. Figure 3A shows a rendering of the X-ray structure of linezolid bound to the 50S subunit of H. marismortui (20) and highlights the position of U2585 (E. coli numbering) with respect to the oxazolidinone binding site. Figure 3B shows the positions of linezolid and U2585 with respect to the CCA ends of A-and P-site tRNAs, showing that oxazolidinones, when bound to this pocket, are able to interfere with A-site tRNA positioning.
R-01 compounds have high binding affinity for the ribosome. Structural studies of Deinococcus radiodurans 50S have
shown chloramphenicol bound at the peptidyl transferase center (40) . Nevertheless, subsequent X-ray studies using 50S from H. marismortui found a second chloramphenicol binding site at the entrance of the peptide exit tunnel (18) . Therefore, we investigated the abilities of R-01 compounds to displace puromycin, in addition to chloramphenicol. Puromycin is the prototypical A-site antibiotic and has been shown by X-ray crystallography to bind in a fashion similar to those of the A site of H. marismortui (18, 32) and D. radiodurans ribosomes (3).
Because R-01 compounds and chloramphenicol protect U2585 from chemical modification by carbodiimide at about the same level, we assessed if R-01 compounds could displace the A-site inhibitor chloramphenicol or puromycin from its ribosome binding site. The chloramphenicol displacement assay showed that members of the R-01 family of compounds displace chloramphenicol with apparent IC 50 s 20-fold lower than that for linezolid (Fig. 4A shows Rx-01_007 and Rx-01_423). The abilities of R-01 compounds to displace chloramphenicol and to protect nucleotide U2585 are well correlated, as shown in Fig. 2 . Equally, the inability of linezolid to protect U2585 is reflected in its poor ability to displace chloramphenicol from the ribosome. Similar experiments using radiolabeled puromycin instead of chloramphenicol showed that Rx-01_149 was able to displace puromycin with an IC 50 100-fold lower than that for linezolid (Fig. 4B) . These results suggest that R-01 compounds bind to the ribosomal A site and confirm that they do so with higher affinity than linezolid.
R-01 oxazolidinones cause translational inaccuracy. Linezolid, chloramphenicol, and other inhibitors that bind to the 50S ribosomal subunit promote frameshifting and readthrough of stop codons (28, 48) . These effects on translational fidelity may play a significant role in the mechanisms of action of these compounds. Therefore, we investigated whether the R-01 compounds were able to promote translational inaccuracy in a fashion similar to that of linezolid. We found that R-01 compounds were able to promote stop codon readthrough two-to fivefold more efficiently than linezolid (Fig. 5A) . Specifically, Rx-01_423-induced stop codon readthrough is five-fold more efficient than that of linezolid, while Rx-01_667 and Rx-01_413 were three-and twofold more efficient than linezolid. The R-01 compounds Rx-01_413 and Rx-01_423 promoted translational inaccuracy as measured by the promotion of a Ϫ1 frameshifting event (Fig. 5B) at extents that were approximately equal to that of linezolid. Rx-01_413 and Rx-01_423 were able to stimulate ϩ1 frameshifting about twofold more efficiently than linezolid, while Rx-01_667 was able to promote both Ϫ1 and ϩ1 frameshifting about threefold more than linezolid (Fig. 5B) , suggesting that this effect could contribute to their antibacterial activities.
DISCUSSION
Here, we report that oxazolidinones of the R-01 family bind to the ribosome with higher affinity than the only marketed oxazolidinone antibiotic, linezolid. In translation assays, members of the R-01 family clearly overcame the most common ribosomal mutation (G2576U) associated with linezolid resistance in the clinic. Moreover, the increase in potency seen in the R-01 novel oxazolidinones does not come at the cost of selectivity; the selectivity ratios of R-01 compounds are comparable to those of linezolid (Table 1) . Furthermore, the abilities of R-01 compounds to displace chloramphenicol or puromycin to a 20-to 100-fold greater extent than linezolid fit well with the compounds' abilities to bind to the ribosome more strongly than linezolid, as well as with their greater abilities to cause translational inaccuracies.
Initiation complex formation has often been portrayed as the target for oxazolidinone antibiotics (43, 47) . However, the ability of oxazolidinones to inhibit initiation complex formation has been observed only at high ratios of oxazolidinones to ribosomes. Moreover, attempts to demonstrate that oxazolidinones inhibit peptide bond formation have not produced clear results, except for the inhibition of the first peptide bond as a consequence of the interference of linezolid with the binding of initiator fMet-tRNA(i)(Met) (35) . Alternative mechanisms of oxazolidinone action have been proposed when experiments showed that oxazolidinones had a significant in vivo effect on frameshifting and nonsense suppression at concentrations below the MIC (48) and were also able to inhibit 50S ribosomal subunit assembly (8) . Clearly, the mechanism of action of oxazolidinones is not fully understood. Nevertheless, like previous publications, this work is consistent with the binding of linezolid to the peptidyl transferase region. The evidence presented here and elsewhere, therefore, provides ample rationale for why all mutations (22, 36, 38, 39, 49, 51) or nucleotide modifications (29) conferring oxazolidinone resistance are located in or close to the peptidyl transferase ring in domain V of 23S rRNA. Not only do R-01 compounds bind to the ribosome with more affinity than linezolid, they also have at least one additional interaction with the ribosome: they protect nucleotide U2585 from chemical modification ( Fig. 2A and B) . U2585 is a nucleotide whose CMCT modification has been shown to interfere with binding of peptidyl-tRNA analogs (6) , and the rate constants for peptidyl transfer for U2585 mutant ribosomes have been reported to be 10-to 500-fold lower (depending on the mutation) than those of wild-type ribosomes (17) . Furthermore, these mutant ribosomes catalyze peptide release at substantially compromised rates (25-to 45-fold) (54) . All of these observations underscore the importance of U2585 for efficient peptide bond formation and peptide release (13) and strongly suggest that antibiotics interacting with U2585 will impact the efficiency of protein synthesis.
Rx-01_002, synthesized as proof of concept for the development of the family of R-01 oxazolidinones, was based on the overlap of the binding sites for linezolid and sparsomycin as determined by X-ray crystallography using the Haloarcula 50S structures in complex with these two antibiotics (20, 45) . We determined that Rx-01_002 inhibits protein translation fueled by wild-type, as well as by linezolid-resistant, S. aureus ribosomes and demonstrated that linezolid resistance could be overcome by enhancing binding affinity to the 50S ribosomal subunit ( Table 1 ). The inhibitory effect of R-01 compounds in in vitro protein synthesis translated, in most cases, into wholecell antibacterial activity against important gram-positive hospital pathogens, including linezolid-resistant enterococci (Table 2) (26) .
Based on our findings, we hypothesize that R-01 oxazolidinones affect the rates of peptide bond formation and release because of their stable interaction with U2585. Compared to linezolid, the R-01 oxazolidinones are able not only to inhibit protein synthesis more efficiently, but also to promote translational inaccuracy more effectively. Since decoding is an event controlled by the 30S subunit, the effect of 50S antibiotics on translational fidelity is likely mediated by tRNAs. Therefore, the abilities of oxazolidinones to negatively influence translational fidelity must be a long-range effect mediated by their abilities to perturb or interfere with tRNA binding and/or tRNA positioning at the peptidyl transferase center. Because R-01 oxazolidinones are able to inhibit protein synthesis more strongly than linezolid, our results support the role of translational fidelity as a significant factor in the mechanism of action of oxazolidinones (48) .
It has been proposed that oxazolidinones bind to the ribosomal P site (5) . Nevertheless, our structural data show that nucleotide U2585 is part of the all-RNA oxazolidinone binding pocket within the ribosomal A site (20) . X-ray structures of the 70S ribosome containing tRNA in the ribosomal A site (42) allow us to conclude that binding of R-01 compounds in the A-site pocket could perturb tRNA binding. Our findings are in very good agreement with a recently published model of linezolid bound to the 50S ribosomal subunit generated from in vivo cross-linking data, which indicates that linezolid interacts with the A-site and interferes with the placement of aminoacyltRNA (27) .
In summary, our structure-based approach successfully yielded the new R-01 family of oxazolidinones, and our biochemical and functional studies helped delineate the mechanism(s) of action of these R-01 compounds. While maintaining its specificity for prokaryotic ribosomes, this family of compounds binds more tightly to ribosomes and is able to inhibit bacterial protein synthesis at concentrations that are (48) carrying reporter plasmids with either stop codon at the N terminus of the lacZ gene were grown in the presence of subinhibitory concentrations of gentamicin (1.5 g/ml), linezolid (8 g/ml), Rx-01_413 (0.5 g/ml), Rx-01_423 (2 g/ml), and Rx-01_667 (1 g/ml). (B) Production of ␤-galactosidase is dependent on frameshifting events. E. coli strains carrying reporter plasmids in which the reading frame of the lacZ gene contained either a ϩ1 or a Ϫ1 frameshift close to the N terminus were grown as described for panel A. Frameshifting and stop codon readthrough values in the absence of antibiotics were set at 1 to allow the relative effects of all antibiotics tested to be compared. The stop codon readthrough and frameshift values obtained for linezolid and for the gentamicin control in this assay were comparable to those obtained by Thompson et al. (48) . The error bars indicate standard deviations.
VOL. 52, 2008 NEW OXAZOLIDINONE FAMILY OVERCOMES LINEZOLID RESISTANCE 3555 more than 100 times lower than that for linezolid while maintaining its specificity for prokaryotic ribosomes. Thus, our compounds are more potent than linezolid against strains with ribosome-based linezolid-resistant mutations. The new R-01 oxazolidinone family also has a broader spectrum of microbiological activity, including fastidious gram-negative and intracellular pathogens. Studies detailing the in vitro potencies versus different community-and hospital-acquired pathogens, including fastidious gram-negative and intracellular pathogens, have been partially presented and published (12, 26) . Overall, our results indicate that the R-01 family of compounds may be well suited to provide new potent antibiotics effective in the clinic against resistant bacteria. A member of the R-01 family of compounds is currently undergoing clinical trials.
